Exhibit 99.1
Joint Filing Agreement
The undersigned hereby agree that the Statement on Schedule 13G dated January 31, 2025 with respect to the Common Stock, $0.0001 par value per share, of Monte Rosa Therapeutics, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
| BIOTECHNOLOGY VALUE FUND L P |
| |
| By: | /s/ Mark N. Lampert | |
| | Mark N. Lampert, Authorized Signatory |
| Date: | 01/31/2025 |
| BVF I GP LLC |
| |
| By: | /s/ Mark N. Lampert | |
| | Mark N. Lampert, Authorized Signatory |
| Date: | 01/31/2025 |
| BIOTECHNOLOGY VALUE FUND II LP |
| |
| By: | /s/ Mark N. Lampert | |
| | Mark N. Lampert, Authorized Signatory |
| Date: | 01/31/2025 |
| BVF II GP LLC |
| |
| By: | /s/ Mark N. Lampert | |
| | Mark N. Lampert, Authorized Signatory |
| Date: | 01/31/2025 |
| Biotechnology Value Trading Fund OS LP |
| |
| By: | /s/ Mark N. Lampert | |
| | Mark N. Lampert, Authorized Signatory |
| Date: | 01/31/2025 |
| BVF Partners OS Ltd. |
| |
| By: | /s/ Mark N. Lampert | |
| | Mark N. Lampert, Authorized Signatory |
| Date: | 01/31/2025 |
| BVF GP HOLDINGS LLC |
| |
| By: | /s/ Mark N. Lampert | |
| | Mark N. Lampert, Authorized Signatory |
| Date: | 01/31/2025 |
| BVF PARTNERS L P/IL |
| |
| By: | /s/ Mark N. Lampert | |
| | Mark N. Lampert, Authorized Signatory |
| Date: | 01/31/2025 |
| BVF INC/IL |
| |
| By: | /s/ Mark N. Lampert | |
| | Mark N. Lampert, Authorized Signatory |
| Date: | 01/31/2025 |
| LAMPERT MARK N |
| |
| By: | /s/ Mark N. Lampert | |
| | Mark N. Lampert |
| Date: | 01/31/2025 |
